Bluedrop Medical and the EIC Accelerator: A Scale for Diabetic Feet

29 September 20261,094 words6 min

People with diabetes often lose feeling in their feet, so wounds can go unnoticed until they become ulcers that, in the worst cases, lead to amputation. Bluedrop Medical, founded in Galway in 2015, built the OneStep Foot Scanner, a device that looks like a bathroom scale and takes high-resolution images and temperature readings of the feet in under 30 seconds a day, with a monitoring service that alerts patients and doctors to early signs of damage.

The EIC selected Bluedrop's NextSTEP project in the October 2021 round, and the EIC Fund invested in a €10.5 million round in March 2023. No NextSTEP grant project with Bluedrop appears in the EU's CORDIS database, so what the grant part of the award paid for cannot be checked. Today Bluedrop runs its service from an office in Houston, Texas, and publishes no user numbers.

€10.5MFunding round with the EIC Fund, March 2023
€16MTotal raised by March 2023
~4Scans a week per patient, company average
0NextSTEP grant projects on CORDIS

Company file

Legal entity
Bluedrop Medical Limited, Galway, Ireland
Founded
2015, by Chris Murphy and Simon Kiersey
Products
OneStep Foot Scanner; EveryStep monitoring service
US base
Bluedrop RPM, Houston, Texas
Investors
Atlantic Bridge, Elkstone, EIC Fund, Furthr VC, Western Development Commission and others
Trials
NCT06053047 (terminated), NCT06782386 (ongoing)
Earlier EIC project
DELTA, EIC SME Instrument Phase 2 (Horizon 2020), 1 Aug 2019 to 30 Nov 2022, €2.50M grant
EIC award
NextSTEP, blended finance; no grant project on CORDIS
Team
17 employees in 2023, planning 25 more

Where Bluedrop Stands Today

Bluedrop's website addresses patients and US healthcare providers, lists a Houston address alongside Galway, and says patients scan on average about four times a week, with "the few ulcers that are detected graded at a Stage 1 at time of clinical escalation". It cites figures that an ulcer caught at Stage 1 costs 57% to 93% less to treat than later stages. Its news page has not been updated since March 2023. On ClinicalTrials.gov, a US re-ulceration trial it sponsored was terminated after 26 patients for "unsustainable recruitment rate", and a second trial with Serena Group, planned for 100 patients, started in February 2025.

The evidence

Bluedrop's US trials

Enrolment in the two trials Bluedrop sponsors on ClinicalTrials.gov: the first was terminated for slow recruitment; the second plans 100 patients.

ClinicalTrials.gov NCT06053047 and NCT06782386.

The Technology: A Daily Foot Check

Patients step on the OneStep scanner, which captures high-resolution images and temperature data of the feet. Bluedrop's EveryStep service reviews the data and contacts patients, and their doctors if needed. The company says the approach limits "unnecessary alerts that can discourage use of any monitoring system over time".

"A simpler way to check your feet, in less than a minute a day."

Bluedrop Medical website

What the EIC Project Promised, and What the Record Shows

Bluedrop's first EIC grant came earlier. At the 3 April 2019 cut-off of the EIC SME Instrument Phase 2, part of the Horizon 2020 EIC pilot, it was selected for DELTA, which ran from 1 August 2019 to 30 November 2022 with an EU contribution of €2,499,850 towards a total cost of €3,571,215, to finish the scanner's hardware and software, obtain regulatory approval and start pilots. The final report says all three were completed, with the approvals required for a US launch in place, and the US Food and Drug Administration's device register has listed a Class I foot examination tool from Bluedrop since April 2022.

NextSTEP promised "next gen remote management of patients suffering from diabetic foot syndrome". The award was blended finance. The EIC Fund's participation in the 2023 round confirms the equity side. We searched the CORDIS Horizon Europe data and found no NextSTEP project with Bluedrop as coordinator; the acronym belongs to an unrelated research project. Whether a grant was signed and paid is not public.

  1. A home monitoring systemDeliveredOneStep and EveryStep on offer.
  2. Clinical evidencePartialOne trial stopped; one ongoing.
  3. Private follow-on capitalDelivered€10.5M in 2023.
  4. A reported NextSTEP grant projectNot shownNot on CORDIS.

What Has Happened Since the Award

The record

From Galway start-up to US foot monitoring service

Bluedrop won EIC awards in 2019 and 2021, took EIC Fund equity in a 2023 round and now runs its monitoring service from Houston; no NextSTEP grant project appears on CORDIS.

  1. 2015FoundedBy Chris Murphy and Simon Kiersey, Galway
  2. Aug 2019EIC SME Instrument Phase 2DELTA: scanner finished and approved for US launch, to Nov 2022€2.50M grant
  3. Feb 2021SBIR contractEnterprise Ireland and HSE diabetes challenge€0.1M
  4. Oct 2021EIC Accelerator cut-offNextSTEP: remote management of diabetic foot syndrome
  5. Mar 2023Funding roundAtlantic Bridge and Elkstone lead; EIC Fund invests€10.5M
  6. Jan 2024US trialRe-ulceration study starts; later stopped for slow recruitment
  7. Feb 2025Second US trialWith Serena Group; 100 patients planned
  8. 2026ServiceOneStep scanner and EveryStep monitoring from Houston

Bluedrop Medical and ClinicalTrials.gov.

The Money

The March 2023 round was co-led by Atlantic Bridge and Elkstone, with the EIC Fund, Furthr VC, the Western Development Commission, Ascentifi and the HBAN MedTech and Irrus Investments syndicates. Bluedrop said it would add 25 jobs to its 17 staff, with engineering in Ireland and commercial roles in the US, and that the round brought its total funding to €16 million.

The money

The 2023 round was most of the money raised

Bluedrop said the March 2023 round brought its total funding to €16M. The EIC Fund's share was not disclosed.

Bluedrop Medical, March 2023. Values in € millions.

What cannot be checked

How many patients use Bluedrop's service, its revenue, whether it has US reimbursement at scale, the EIC Fund's share and whether any NextSTEP grant was paid are not public.

Why Europe Should Care

Bluedrop's own figures put the US cost of diabetic foot ulcers at more than $17 billion a year, and its service is aimed at US patients and providers. EU money helped an Irish company pursue that market. Whether European patients benefit is not yet visible.

What the project promised

Next-generation remote management of patients with diabetic foot syndrome.

What the record shows

A US monitoring service, €10.5M raised with the EIC Fund, one trial stopped and one ongoing; no grant record.

The Verdict

A product in the US, a gap in the EU record

Bluedrop has a product on offer and investors including the EIC Fund. But its clinical evidence is still being built after a trial that failed to recruit, and the grant side of its 2021 EIC award has left no public record.

Bluedrop Medical has not been asked for comment for this article. It is based entirely on company statements, EU data and the trial registry, linked throughout.

Industry

HealthMedical devices

AlsoHealthDigital health

Focus
  • Diabetes devices
  • Remote care
Technologies
  • Thermal imaging
Keywords
  • Diabetes
  • Diabetic foot ulcers
  • Amputation prevention
  • Home monitoring